Table 6. Incidence of infection related... | Rockefeller University Press

Table 6.

Incidence of infection related to CGD

Group	Period	Frequency	Incidence rate	95% CIs (lower, upper limits)	Difference in incidence rate	95% CIs of the difference (lower, upper limits)	Incidence rate ratio	95% CIs of the ratio (lower, upper limits)
Thalidomide (n = 3)	24 wk before administration	7	5.07	2.04, 10.45	4.71	−3.97, 13.39	1.93	0.54, 6.70
Thalidomide (n = 3)	24 wk after administration	6	9.78	3.59, 21.30	4.71	−3.97, 13.39	1.93	0.54, 6.70
Placebo (n = 5)	24 wk before administration	12	5.22	2.70, 9.12	2.14	−4.45, 8.72	1.41	0.43, 4.06
Placebo (n = 5)	24 wk after administration	6	7.35	2.70, 16.01	2.14	−4.45, 8.72	1.41	0.43, 4.06
All (n = 8)	Extension phase	6	3.51	1.29, 7.63	–	–	–	–

Group	Period	Frequency	Incidence rate	95% CIs (lower, upper limits)	Difference in incidence rate	95% CIs of the difference (lower, upper limits)	Incidence rate ratio	95% CIs of the ratio (lower, upper limits)
Thalidomide (n = 3)	24 wk before administration	7	5.07	2.04, 10.45	4.71	−3.97, 13.39	1.93	0.54, 6.70
Thalidomide (n = 3)	24 wk after administration	6	9.78	3.59, 21.30	4.71	−3.97, 13.39	1.93	0.54, 6.70
Placebo (n = 5)	24 wk before administration	12	5.22	2.70, 9.12	2.14	−4.45, 8.72	1.41	0.43, 4.06
Placebo (n = 5)	24 wk after administration	6	7.35	2.70, 16.01	2.14	−4.45, 8.72	1.41	0.43, 4.06
All (n = 8)	Extension phase	6	3.51	1.29, 7.63	–	–	–	–

Infections in the thalidomide group and placebo group were assessed by extracting data from medical records prior to initiation of the investigational drug and aggregating data during the blinded phase (12 wk) and the subsequent extension phase (12 wk). 95% CIs, 95% confidence intervals.

[ViewLarge]

Sharing Unavailable